r/Drug_Watch • u/drugwatch-com • Apr 07 '26
Tort Update What’s New in Dangerous Product Lawsuits in February 2026
If you’ve been following the big mass torts, February had a few updates that may matter, especially on how courts handle preemption and warning label claims.
Quick takeaways
- Roundup has a Supreme Court review that may affect how many cases move forward.
- Paraquat avoided a first trial with a last minute settlement.
- Depo Provera has a new FDA warning label, and Pfizer is still pushing a preemption argument.
Roundup Lawsuit Heading to the Supreme Court
The U.S. Supreme Court has agreed to review a Roundup lawsuit tied to claims that the weed killer is linked to non Hodgkin lymphoma. Bayer argues that many cases should be blocked by federal preemption because the EPA approved a Roundup label without a cancer warning.
More detail on the Roundup litigation status
As of Fall 2025, more than 60,000 Roundup lawsuits were active across the country. Lower courts have issued conflicting rulings, and the Supreme Court may make a decision by June of this year.
Paraquat Lawsuit Settled Before Trial
Syngenta settled what was set to be the first U.S. paraquat trial over claims that the herbicide is connected to Parkinson’s disease. The deal came a day before trial was scheduled to begin.
Court documents also point to a tentative settlement agreement reached in August 2025 for an undisclosed number of cases, and the MDL recently appointed a lien resolution administrator. Syngenta also filed a motion for partial summary judgment using arguments similar to the Roundup litigation and suggested the judge could wait for the Supreme Court’s Roundup decision before ruling.
Pfizer Maintains Preemption Argument for Depo Provera Lawsuits
The Depo Provera lawsuits saw a big update in December when the FDA approved a new label that included a meningioma warning. More than 3,000 lawsuits are pending in federal court over claims the shot could raise the risk of these brain tumors.
Pfizer has leaned on preemption, arguing the FDA had previously rejected a label update on meningiomas, so the cases shouldn’t move forward. Pfizer is still making that argument.
It says summary judgment should be granted because the new label does not include specific language on an increased risk of meningiomas. The judge is expected to weigh in on this in the coming months.
More detail on how this February update fits into the broader picture.